Transcutaneous Auricular Vagus Nerve Stimulation Treatment on Reflux Esophagitis

Overview

Objective: To evaluate the effect of Transcutaneous auricular vagus nerve stimulation for the patients reflux esophagitis. Methods: We accrued 29 patients at Beijing TongRen Hospital Affiliated to Capital Medicine University of. All treatments were self-administered by the patients at home after training at the hospital. Patients completed questionnaires at baseline and after 4 weeks, 8 weeks, 12 weeks and 24 weeks. Endoscopy, reflux diagnostic questionnaire (RDQ), gastrointestinal symptom rating scale (GSRS), and SF-36 were performed to evaluate the therapeutic effects. A difference of P < 0.05 was considered statistically significant.

Full Title of Study: “Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Reflux Esophagitis: a Pilot Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 1, 2020

Interventions

  • Device: Transcutaneous Auricular Vagus Nerve Stimulation
    • to use taVNS to treat Reflux Esophagitis

Arms, Groups and Cohorts

  • Experimental: taVNS
    • Transcutaneous Auricular Vagus Nerve Stimulation

Clinical Trial Outcome Measures

Primary Measures

  • Mean change from Baseline in the reflux diagnostic questionnaire(RDQ) at 12 Weeks
    • Time Frame: Day 0 and postintervention at Week 12
    • The RDQ was used to assess the subjective reflux symptoms covering a 1-wk recall period. RDQ is categorized into four symptom clusters depicting heartburn, chest pain, acid reflux, and food reflux. The total RDQ scores (eight items) were calculated. Patients with RDQ ≥ 12 points were considered to have a relapse.

Secondary Measures

  • Mean change from Baseline in the Gastrointestinal symptom scale(GSRS) rating scale at 12 Weeks
    • Time Frame: Day 0 and postintervention at Week 12
    • GSRS to measure the subjective gastrointestinal symptoms
  • Mean change from Baseline in the 36-items Short Form(SF-36) at 12 Weeks
    • Time Frame: Day 0 and postintervention at Week 12
    • SF-36 to measure quality of life

Participating in This Clinical Trial

Inclusion Criteria

1. Age >=18 and Age <=70. 2. Clinical diagnosis of reflux diagnostic. Exclusion Criteria:

1. History of cirrhosis, renal impairment, tumors, thyroid disease, diabetes, Crohn's disease, or ulcerative colitis. 2. History of GI or abdominal surgery. 3. Pregnant or lactating women.

Gender Eligibility: All

Minimum Age: 41 Years

Maximum Age: 66 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Beijing Tongren Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: wudong0120, Doctor – Beijing Tongren Hospital
  • Overall Official(s)
    • Haihong Lian, Doc, Principal Investigator, BeijingTongren Hospital, Capital Medical University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.